References
- Shams P, Plant G. Optic neuritis: a review. Int MS J. 2009;16(3):82–89.
- Balcer LJ. Clinical practice. Optic neuritis. N Engl J Med. 2006;354(12):1273–1280.
- Etemadifar M, Maghzi AH. Sharp increase in the incidence and prevalence of multiple sclerosis in Isfahan, Iran. Mult Scler. 2011;17(8):1022–1027.
- American Academy of Ophthalmology RF. Basic and Clinical Science Course (BCSC), Section 5: Neuro-Ophthalmology. 2015–2016:105–122.
- Wilhelm H, Schabet M. The diagnosis and treatment of optic neuritis. Dtsch Arztebl Int. 2015;112(37):616–625; quiz 626.
- Hayreh SS. Ischemic optic neuropathies - where are we now? Graefes Arch Clin Exp Ophthalmol. 2013;251(8):1873–1884.
- Smolensky MH, Portaluppi F, Manfredini R, et al. Diurnal and twenty-four hour patterning of human diseases: acute and chronic common and uncommon medical conditions. Sleep Med Rev. 2015;21:12–22.
- Kohler A, Chaves H, Negrotto L, et al. Pineal Gland Size and Risk of Multiple Sclerosis (P4. 182). Neurology. 2016;86:16–182. (Supplement)P4.
- Melamud L, Golan D, Luboshitzky R, et al. Melatonin dysregulation, sleep disturbances and fatigue in multiple sclerosis. J Neurol Sci. 2012;314(1-2):37–40.
- Aranda ML, Gonzalez Fleitas MF, De Laurentiis A, et al. Neuroprotective effect of melatonin in experimental optic neuritis in rats. J Pineal Res. 2016;60(3):360–372.
- Frohman TC, Davis SL, Beh S, et al. Uhthoff's phenomena in MS-clinical features and pathophysiology. Nat Rev Neurol. 2013;9(9):535–540.